How can we make the process of developing medications faster, safer, and less costly?
An ever-greater understanding of disease processes has made it possible to develop medications that are customised for specific patients or groups of patients. However, the process is expensive, time-consuming, and risky. TNO is working on innovations to make it easier to develop medications more quickly, more safely, and cost effectively.
Our starting point is that the innovations should be designed to accelerate the process. After all, a shorter and more efficient development process would reduce costs and result in medications being available more quickly. One such cost-saving innovation is the Accelerator Mass Spectrometry (AMS). This is a unique technology that could prevent delays in the development of new medications. Other examples are a 3D printer for printing ‘custom-made’ medications, an organ-on-a-chip, and models of organs for reducing the likelihood of new medications failing during the clinical trial phase.
But the fact is that the only way of making substantial improvements to the process by which medications are developed is to do so in a coordinated and concerted manner. We should then be in a position to develop ever-more complex and personalised medications for patients, using less animal testing and at an acceptable level of cost.
Six important aspects
Below are the most important recommendations for the pharmaceutical industry and government for successfully accelerating the process:
- Identify the bottlenecks that lead to higher costs and greater risks, as well as the opportunities for accelerating that process.
- A coordinated approach, involving government, industry, and TNO (as an independent knowledge partner) could make possible the development of more complex medications at an acceptable cost.
- With a coordinated approach, government and industry could make more targeted investments in relevant process innovations.
- By being directly involved, the government could introduce and implement the necessary regulations more quickly.
- More carefully targeted innovation would reduce the risks, while an integrated approach for speeding up the process could save billions of euros.
- In a dialogue between the pharmaceutical industry and government, these savings should feed through to lower prices for medications.
Want to join us in improving drug development of the future? Get in touch with Ivana Bobeldijk.
TNO helps accelerate drug development through insight
To find the most effective interventions for complex metabolic diseases, we must first understand the dynamics of disease onset and progression. Only then can key targets and optimal therapeutic windows for more effective treatment be defined. We spoke with Anita van den Hoek, Research Scientist for TNO Metabolic Health, about how TNO helps pharmaceutical companies accelerate drug development through better understanding of disease pathways.
TNO proves method for effective pediatric drug development
Safe and effective drug dosing for young children come with their own challenges. Up to the age of 18, a child’s metabolism can change significantly. And in the first two years of life, those ontogenic differences can be rapid and dramatic. TNO published its findings from the first drug disposition (mass balance/metabolite profiling) study to conclusively prove that microtracing with accelerator mass spectrometry (AMS) is an effective way to collect clinical data in these young patients. This AMS technology can also be the key to building up more data on drug interventions in pregnant and lactating mothers.
Functional microbiome analysis
TNO has a wide range of available tools to increase understanding of the impact and interaction of the microbiome on human health. Learn more.
Target safety assessment
Our unique set of assessments and web-based target triaging platform TargetTri, can help to make informed decision making easy with transparent, knowledge-driven expert views on target efficacy, safety liabilities, and risk mitigation.
PK Studies AMS
With TNO’s microtracer expertise, drug development becomes a streamlined and targeted process.